TNFα deficiency results in increased IL-1β in an early onset of spontaneous murine colitis by De Santis, S et al.
OPEN
TNFα deficiency results in increased IL-1β in an early
onset of spontaneous murine colitis
S De Santis1,2, D Kunde3, V Galleggiante1, M Liso1, L Scandiffio1, G Serino1, A Pinto4, P Campiglia4, R Sorrentino4, E Cavalcanti1,
A Santino2, ML Caruso1, R Eri3 and M Chieppa*,1,4
Inflammatory bowel disease (Crohn’s disease (CD) and ulcerative colitis (UC)) is a multifactorial disease resulting from immune
dysregulation in the gut. The underlying colitis is characterized by high levels of inflammatory cytokines, including TNFα.
Biological intervention for IBD patients using anti-TNFα antibodies is often an effective therapeutic solution. However, TNFα
neutralization fails to induce remission in a subgroup of IBD patients, primarily in UC patients. There is a dearth of suitable animal
models representing TNFα non-responders. Here we have combined one of the best UC models currently available, namelyWinnie
and the TNFαKO mouse to generate a TNFα-deficient Winnie to study early onset colitis. The induced TNFα deficiency with
underlying colitis does not influence general health (viability and body weight) or clinical parameters (colon weight, colon length
and histological colitis) when compared with the Winnie genotype alone. The molecular characterization resulted in identification
of Il1β as the major elevated cytokine during early phases of colitis. Further, in vitro functional assay using bone marrow-derived
dendritic cells confirmed IL-1β as the major cytokine released in the absence of TNFα. This study has generated a successful
model of colitis that remains TNFα non-responsive and has demonstrated that IL-1β expression is a major pathway for the
progression of colitis in this system. These data also suggest that IL-1β can be a potential target for clinical intervention of UC
patients who fail to respond to TNFα neutralization.
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Inflammatory bowel diseases (IBD) include Crohn’s disease
(CD) and ulcerative colitis (UC), which are both chronic
relapsing inflammatory disorders of the gastro-intestinal tract.1
The mucosal immune system is dynamically regulated to a
state of tolerance to luminal antigens including commensal
bacteria and food-derived antigens. However, breaches of
mucosal immune tolerance can occur due to both environ-
mental and genetic factors resulting in perturbed intestinal
homeostasis. Several different events can trigger inflamma-
tory responses that may result in chronic inflammation and
pathological changes associated with IBD. A common ground
for this multifactorial disorder is an increased production of
diverse panel of cytokines,2,3 some of which are pro-
inflammatory and hence targets for therapeutic blockade.4
Among the cytokine milieu dysregulated in IBD-like chronic
inflammatory conditions, tumor necrosis factor α (TNFα) is a
major pro-inflammatory cytokine that drives downstream
immune responses resulting in IBD. Colonic macrophages
are reported to be the major source of TNFα in active IBD.5
Studies of macrophages isolated from the colon of patients
with active IBD have reported elevated TNFα production.6,7
Additionally, TNFα is also produced by numerous other
immune cells such as T and B lymphocytes,8,9 intestinal
epithelial cells10 and several other cells.11 It is well known that
TNFα polymorphisms result in increased pathogenic TNFα-
driven intestinal gut pathology in CD.12 Clinical investigations
have led to the discovery of anti-TNFα monoclonal antibodies
(Infliximab and others) which have dramatically changed the
medical approach to IBD.
Similar to CD, a subgroup of UC patients also exhibit
increased TNFα levels in the colon. In fact, Braegger et al.13
reported the presence of TNFα in stool samples in such UC
patients. Numerous studies have confirmed the crucial role of
TNFα in colitis.14,15 Results obtained by Corazza et al. were
particularly relevant in exploring the role of TNFα in the onset
of UC. Using TNFαKO murine models they were able to
demonstrate the importance of TNFα production by non-T
cells of the colonic mucosa in the pathogenesis of colitis.16
However, there is a subgroup of human IBD non-responders to
anti-TNFα therapies, particularly in the UC cohort.17 Animal
models have significantly contributed to the elucidation of the
pathological mechanisms of IBD and to the validation of
immunological targets for IBD treatment.18 However, using the
currently available murine models we are unable to decipher
the exact mechanism as to why some subgroups of UC
patients do not respond to anti-TNFα therapies.
In order to address the lack of a model with relevance to the
anti-TNFα non-responding UC patient group we planned to
develop a viable model based on the best recently described
murine model of UC currently available, namely Winnie.
Winnie colitis is due to amissensemutation in theMuc2mucin
gene19 resulting in spontaneous distal colitis developing as
early as 5 weeks of age. In the Winnie mouse the colonic
pathology is predominantly mediated by the dysregulation of
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numerous cytokines, including elevated TNFα similar to
human UC where the intestinal inflammation is most severe
in the distal colon and the disease severity increases with
age.20 In order to remove the effect of TNFα in the Winnie
spontaneous colitis, we generated Winnie/TNFα knockout to
explore the axis between TNFα and intestinal inflammation
that may resemble UC non-responders to anti-TNFα
therapies,21,22 or patients who become non-responder
(secondary non-responder) in the absence of anti-Infliximab
antibodies.23
Detailed histological and immunological assessment of
early differences between Winnie and TNFα KO Winnie
revealed that TNFα KO Winnie exacerbates pathogenesis
associated with an increased inflammatory cytokines secre-
tion, particularly IL-1β. Furthermore, elevated Il1β transcrip-
tion was detectable in 5-week-old mice prior to the onset of
morphological signs of UC, suggesting that this cytokine may
represent a predictive biomarker for UC patients who are
non-responder to anti-TNFα therapy and possibly an
alternative target for combinatorial biological approaches.
Results
TNFα deficiency does not influence general health and
clinical parameters. TNFα is commonly considered the
primary immunological target for IBD treatment. To investi-
gate the axis between TNFα and UC onset, we used a
breeding strategy based on double heterozygote breeders
(Figure 1a) to obtain the double mutants and all the controls
from the same breeding pair. This strategy permitted the
evaluation of viability and weight of the offspring depending
on the different genotypes and independently from differ-
ences related to diverse mothers. Results shown in Figure 1a
demonstrate that all the resulting strains were viable and no
significant variation from the predicted genotype (6.25%) was
obtained in the 4-week-old offspring.
Figure 1b shows that significant differences inmouseweight
could be seen in 4-week-old mice from different genotypes.
Overall, Winnie and TNFα KO Winnie (both male and female)
mice were lighter (8.28± 0.23 and 8.76± 0.39, respectively)
than WT (C57/BL6) and TNFα KO controls (12.59± 0.31 and
12.39± 0.46, respectively). Between Winnie and TNFα KO
Winnie there was no difference in body weight. These results
show that mice carrying the Winnie mutation had lower body
weight independently from TNFα.
TNFα deficiency does not influence the initial develop-
ment of intestinal inflammation. Macroscopic or histologi-
cal colitis as demonstrated by colon shortening and
hematoxylin and eosin (H&E) histological scoring of inflam-
mation in C57/BL6 mice (7.22±0.42) was not significantly
different from TNFα KO mice (6.81± 0.15); however, the
colon length of both groups were significantly longer than
Winnie (6.01± 0.27) and TNFα KO Winnie (6.13±0.20) if
compared with WT mice (Figures 2a and b). The differences
were much more striking when adjusted for body weight
(Figure 2c).
Detailed histological analysis (ulceration, re-epithelization,
transmural inflammation and chronic inflammation) revealed a
similar picture where there was no difference in inflammatory
scores between C57/BL6 mice and TNFα KO mice while the
inflammatory scores being higher in Winnie and TNFα KO
Winnie (Figures 2d and e). However, there was no difference
between Winnie and TNFα KO Winnie cohorts.
TNFα deficiency results in elevated expression of Ifnγ
and Il1β during early onset colitis. The cytokine expres-
sion and secretion signatures responsible for the increased
inflammation in Winnie and TNFα KO Winnie were investi-
gated to identify any potential molecular mechanisms
mediated by TNFα during early onset colitis. We employed
a panel of cytokine markers of Th1 (Il1β, Ifnγ and Il12), Th2
(Il4, Il10), Th17 (Il17a) and T-regs (Foxp3) populations to
specifically quantify the relative gene expression across all
cohorts by qPCR. Relative expression analysis revealed a
striking elevation of Il1β (Figure 3a) and Ifnγ (Figure 3b) in
TNFα KO Winnie mice compared with all other mice strains.
Strikingly, in the Winnie background, the absence of TNFα
leads to a molecular pathway that results in a pattern
suggestive of an increased Th1 signature. The Th1-
promoting cytokine Il12 (Figure 3c) was also upregulated in
TNFα KO Winnie, reinforcing the elevated Ifnγ observed. The
expression of the anti-inflammatory cytokine Il10 was also
increased in Winnie and TNFα KO Winnie (Figure 3d),
although the ratio between Il12 and Il10 is higher in TNFα KO
Winnie. Furthermore, both in Winnie and TNFα KO Winnie,
we observed a higher expression of the Th2 cytokine Il4
(Figure 3e) compared with controls. The expression of Il17a
and Foxp3 was also evaluated, but results were below
detection.
Additionally, we evaluated the mechanism behind TNFα
negative feedback on IL-1β secretion. In particular, we
compared NLRP3 and caspase-1 activation in Winnie and
TNFα KOWinnie intestinal samples. In line with the increased
IL-1β secretion, we observed a marked increase in the levels
of NLRP3 activation inWinniemice particularly in the absence
of TNFα (Figure 4a). The level of caspase-1 activation was
increased in Winnie compared with WT, but the absence of
TNFα strongly affected caspase-1 activation, which resulted in
approximately doubled expression levels in TNFα KO Winnie
(Figure 4b). Finally, we evaluated the serum levels of cytokines
of 5-week-old mice (4 mice per group) by Bead-based
Multiplex assay. Among the pro/anti-inflammatory molecules
analyzed, IL-6 was elevated in the serum ofWinnie and TNFα
KO Winnie compared with the control, approximately two and
three times higher, respectively, (Figure 5a). IFNγ and IL-1α
were elevated in the TNFα KO Winnie serum (Figures 5b and
c, respectively). Serum IL-1β was not increased in TNFα KO
Winnie (data not shown), suggesting that systemic secretion
of IL-1β was low, perhaps due to the early age and level of
colitis.
TNFα modulates IL-1β secretion in TNFα KO bone
marrow-derived dendritic cells. To investigate the func-
tional interaction between TNFα and IL-1β, we used bone
marrow-derived dendritic cells (BMDCs) from wild type and
TNFα KO mice. Figure 6a shows that 24 h after LPS
administration, significantly higher IL-1β concentrations were
detected in the supernatant of TNFα KO BMDCs as well as
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higher expression of Il-1β was detected in TNFα KO BMDCs
exposed to LPS (Figure 6b). Addition of TNFα to TNFα KO
BMDCs modulated IL-1β secretion to the same level as
wild-type BMDCs (Figure 6a). We further evaluated the effect
of TNFα by the administration of anti-TNFα in the BMDCs
supernatant. Figure 6a shows that in wild-type BMDCs, TNFα
depletion did not affect IL-1β secretion whereas TNFα KO
BMDCs restored IL-1β secretion (Figure 6a) consistent with
our observation in colitis.
Discussion
In 1998 the introduction of biological therapies with blocking
antibodies against TNFα for CD patients represented a
revolutionary change for the therapy of these patients. It is
now well established that the majority of IBD patients are
responsive to the anti-TNFα therapy, but a significant
percentage (up to 40% in some groups of UC) can be defined
as primary non-responsive.21,22 In this study we have
described a potentially important mechanism linking TNFα-
mediated inflammatory cytokine control through IL-1β. The
murine model developed in this study incorporates a TNFα
deficiency on a background of increased colitis that is closely
representative of UC non-responders.
Murine models of IBD have been successfully used for the
understanding of the biological basis of the disease and for the
development of new drugs.24 Studies pioneered by Corazza
et al.16 dissected the different role of the lymphocyte-derived
TNFα for colitis induction. Although TNFα is a pivotal factor for
the initiation of the inflammatory response, the absence of
TNFα is deleterious inmurinemodels of inflammatory disorders
including experimental autoimmune encephalomyelitis25 and
dextran sodium sulfate-induced colitis.26 The shortcomings of
the aforementioned murine models needed to be addressed in
order to investigate the role of TNFα in UC non-responders.
Among the available models, we used the spontaneous colitis
model (Winnie) characterized by chronic intestinal inflammation
resulting from a missense mutation in the Muc2 mucin gene.19
In Winnie, the defective mucus layer and increased intestinal
permeability result in a spontaneous intestinal inflammation of
the distal colon. To investigate predictive markers of TNFα-
independent UC in a spontaneous and progressive colitis
model, we crossedWinniemicewith TNFαKO (commercial line
5540) to create double KO mice (TNFα KO Winnie).
We crossed heterozygote mice to obtain all the required
strains from the same breeding stock. From the genotype
analysis we confirmed that all strains were viable. In our
system the well-documented association between TNFα
Figure 1 Generation and characterization of the new TNFα KOWinniemurine model. (a) TNFα KOWinniemice were generated by breeding double heterozygote breeders
for TNFα andWinnie genes to obtain the double mutants and all the controls from the same breeding pair. All the resulting strains were viable and no significant variation from the
predicted genotype was obtained in the 4-week-old offspring. (b) Weight analysis of 4-week-old mice from different genotypes reveals a significant decrease in body weight in
mice carrying the Winnie mutation independently of the TNFα phenotype in both males and females. Statistical evaluation between C57/BL6 mice and each murine line was
performed using unpaired two-tailed Student’s t-test. ***Po0.001, **Po0.01, *Po0.05
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deficiency and low body weight was observed only for male
mice even if at a lesser extent. Instead, the Winnie genotype,
independently from TNFα, shows a marked reduction in the
body weight. Macroscopic and histological assessment of the
colon also suggest that the intestinal inflammation in the
Winniemodel was not affected by TNFα deficiency. Our study
shows that in the absence of TNFα there is a significant
compensatory increase in IL-1β production. This observation
Figure 2 Macroscopic and histological characterization of the TNFα KO Winnie. Representative images of dissected colons (a) and measures of colon length (b) from the
new transgenic line and the relative controls indicate a significant reduction in Winnie and TNFα KO Winnie compared with WT. This observation is strikingly evident when the
colon length is adjusted for the body weight (c). Hematoxylin and eosin staining of 3 μm sections of colon (d) and the average score of inflammation (e) show no significant
differences between the TNFα KOWinnie and the controls. Statistical evaluation between C57/Bl6 mice and each murine line was performed using unpaired two-tailed Student’s
t-test. ***Po0.001, *Po0.05
Figure 3 TNFα KO Winnie mice show an increased Th1 signature at the molecular level. mRNA was extracted from the colon of all the 5-week-old mice genotypes. The
expression level of Il1β, Ifnγ, Il12, Il10 and Il4 was measured by qPCR and normalized to the housekeeping gene Gapdh (a, b, c, d, e, respectively). Bars represent mean relative
expression± S.E.M. (n= 4) for each genotype. Statistical evaluation between C57/Bl6 mice and each murine line was performed using unpaired two-tailed Student’s t-test.
***Po0.001, **Po0.01, *Po0.05
Increased IL-1β in an early onset of spontaneous murine colitis
S De Santis et al
4
Cell Death and Disease
is even more interesting in the context of young mice (5-week-
old) that do not yet show morphological signs of inflammation,
including accumulation of inflammatory cells. Additionally, we
also demonstrated that following LPS exposure, TNFα KO
DCs produce three times the amount of IL-1β compared with
WT DCs and that exogenous TNFα administration can delete
the observed difference. Both these evidences point to a
functional role for IL-1β in the pathogenesis of IBD. Recent
research suggest that IL-1β secretion is mainly mediated by
the inflammasome activation in general and NLRP3 in
particular.27 Our data indicate that inflammasome activation
may be a key aspect of protection in the absence of TNFα. We
also observed an increased expression of Ifnγ and Il4 in the
absence of TNFα. It is not surprising to observe these results
given a similar scenario to that observed inWinniewhen IL-17
is blocked with anti-IL-17 antibodies in vivo.28
TNFα KO mice were previously described as a model
mounting a vigorous, disorganized inflammatory response
leading to death in response to the injection with heat-killed
Corynebacterium parvum.29 TNFα anti-inflammatory proper-
ties were previously known, but mainly attributed to the ability
to induce T-cell apoptosis.30 Here we demonstrate that TNFα
KO DCs produce large amounts of IL-1β, an inflammatory
cytokine detectable in patients with active UC.31 Our data
suggest the existence of a negative feedback between TNFα
and IL-1β as recently noticed by West et al.,32 indicating IL-1β
as one of the predictivemarkers for anti-TNFα non-responders
during colonic onset of inflammation.
In conclusion, we believe we have described a valuable
model that closely represents a cohort of UC patients that are
non-responsive to current anti-TNFα therapies and also
identified a potential biomarker for UC non-responders to
Figure 4 Ileum homogenates show higher expression of NLRP3 and active form of caspase-1 in TNFα KO Winnie. Western blot analyses showed that the expression of
NLRP3 (a) was higher in both Winnie and TNFα KOWinniemice. Similarly, (b) the active form of caspase-1 (25 kDa) was significantly higher in both Winnie and TNFα KOWinnie
mice. Quantitative data (bar graphs) were obtained by using ImageJ (NIH, USA) software. Statistical analysis was performed by using one-way ANOVA followed by Tukey’s
multiple comparison as post-test. ***Po0.001, **Po0.01, *Po0.05
Figure 5 TNFα KOWinniemice secrete high levels of circulating inflammatory cytokines. Circulating levels of IL-6, IFNγ and IL-1α (a, b and c, respectively) were determined
by Bead-based Multiplex assay from serum samples of 5-week-old TNFα KO Winnie and all the control lines. Bars represent mean cytokines concentration±S.E.M. (n= 4).
Statistical evaluation between C57/Bl6 mice and each murine line was performed using unpaired two-tailed Student’s t-test. ***Po0.001, *Po0.05
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anti-TNFα therapies. Further research to functionally char-
acterize the role of IL-1β would be the next step in targeted
combinatorial therapy in UC non-responders patients.
Material and Methods
Mice. Investigation has been conducted according to national and international
guidelines and has been approved by the authors' institutional review board
(Organism For Animal Wellbeing – OPBA). The new murine transgenic line TNFα
KO Winnie was created by breeding heterozygous mice from TNFα knockout line
and heterozygous Winnie mice, a murine line established from Dr. Eri’s group at the
University of Tasmania. The TNFα knockout murine line was purchased from
Jackson Laboratories (B6.129S-Tnftm1Gkl/J, stock No: 005540; weight: approxi-
mately 20 g) (Bar Harbor, ME, USA).
All animal experiments were carried out in accordance with Directive 86/609 EEC
enforced by Italian D.L. n. 116 1992, and approved by the Committee on the Ethics of
Animal Experiments of Ministero della Salute – Direzione Generale Sanità Animale
(768/2015-PR 27/07/2015) and the official RBM veterinarian. Animals were killed if
found in severe clinical condition in order to avoid undue suffering.
Histological examination. Tissue section from the distal colon were fixed in
10% buffered formalin and embedded in paraffin. Sections of 3 μm were stained
with H&E. Images were acquired using Leica LMD 6500 (Leica Microsystems,
Wetzlar, Germany). The histological score was calculated by adding the values
relative to the following parameters: ulceration (0–3), re-epithelization (0–3),
transmural inflammation (0–3) and chronic inflammation (0–3).
RNA extraction and qPCR analysis. Total RNA was isolated from the
medial part of the large intestine. The RNA was extracted using TRIzol (Thermo
Fisher Scientific, MA, USA) according to the manufacturer’s instructions. Five
hundred nanograms of total RNA was reverse transcribed with the High Capacity
cDNA Reverse Transcription kit (Thermo Fisher Scientific) by using random primers
for cDNA synthesis. Gene expression of Il1β, Ifnγ, Il12, Il10, Il4 and Gapdh was
performed with TaqMan gene expression assays (Thermo Fisher Scientific) murine
probes: Mm00434228_m1, Mm01168134_m1, Mm01288989_m1, Mm00439614
_m1, Mm00445259_m1, Mm99999915_g1, respectively. Real-time analysis was
performed on CFX96 System (Biorad, Hercules, CA, USA) and the expression of all
target genes was calculated relative to Gapdh expression using the ΔΔCt method.
Multiplex cytokine ELISA. Serum from 5-week-old male mice of each
experimental group was analyzed using the Bead-based Multiplex for the Luminex
platform (LaboSpace srl, Milano, Italy).
Generation and culture of murine DCs. BMDCs were obtained from
TNFα KO mice (5540 line). Briefly, single-cell suspension of BMDCs cells from the
tibiae and femurs of 6- to 8-week-old male mice were flushed with 0.5 mM EDTA
(Thermo Fisher Scientific), and depleted of red blood cells with ACK lysing buffer
(Thermo Fisher Scientific). Cells were plated in a 10 ml dish (1 × 106 cells/ml) in
RPMI 1640 (Thermo Fisher Scientific) supplemented with 10% heat-inactivated fetal
bovine serum (Thermo Fisher Scientific), 100 U/ml penicillin (Thermo Fisher
Scientific), 100 mg/ml streptomycin (Thermo Fisher Scientific), 25 μg/ml rmGM-CSF
(Miltenyi Biotec, Bergisch Gladbach, Germany), and 25 μg/ml rmIL-4 (Miltenyi
Biotec) at 37 °C in a humidified 5% CO2 atmosphere. On day 5 cells were
harvested, re-stimulated with new growth factors and plated 1 × 106 cells/ml on
24-well culture plate. On day 7 BMDCs were stimulated with 1 μg/ml of LPS (L6143,
Sigma-Aldrich, St Louis, MO, USA) and, at the same time, with TNFα standard
(40 ng/ml) and anti-TNFα or anti-IL-1β antibody (400 ng/ml and 80 ng/ml,
respectively). Supernatants were collected 24 h after LPS stimulation.
Western blot analysis. Ileum were homogenated as already reported by
Terlizzi et al.33 Homogenized samples were used to examine the expression of
NLRP3 (AbCam, UK) and caspase-1 active form (25 kDa; AbCam, Cambridge, UK).
Quantitative data were evaluated by means of ImageJ (NIH, Bethesda, MD, USA)
software.
ELISA. Cell culture supernatants were analyzed for IL-1β release in triplicate,
using an ELISA kit (R&D Systems, Minneapolis, MN, USA) following the
manufacturer’ instructions.
Statistical analysis. Statistical analysis was performed using the Graphpad
Prism statistical software release 5.0 for Windows XP. All data were expressed as
means± S.E.M. of data obtained from at least three independent experiments. We
evaluated statistical significance with two-tailed Student’s t-test, one-way ANOVA
followed by Tukey’s multiple comparison as post-test and the two-way ANOVA test
using the Bonferroni as a post-test for the grouped analysis. Results were
considered statistically significant at Po0.05.
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Figure 6 IL-1β upregulation in TNFα KO BMDCs. BMDCs were cultured from WT (black bars) and TNFα KO (white bars) mice, treated with TNFα and anti-TNFα antibody at
day 7 and concomitantly exposed to 1 μg/ml of LPS. Twenty-four hours later, the secretion of IL-1β was determined by ELISA (a). Bars represent mean cytokine
concentration±S.E.M. (n= 3). For each treatment statistical evaluation between WTand TNFα KO DCs was performed using two-way ANOVA and Bonferroni as post-test. For
TNFα KO DCs treated with LPS, paired two-tailed Student’s t-test was conducted to compare BMDCs treated or untreated with TNFα. The expression level of Il1β was measured
in WT and TNFα KO DCs by qPCR and normalized to the housekeeping gene Gapdh. Bars represent mean relative expression±S.E.M. (n= 4) (b). Statistical evaluation
between WT and TNFα KO DCs was performed using unpaired two-tailed Student’s t-test. *Po0.05, **Po0.01, ***Po0.001
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